The pharmaceutical company first set out to acquire Ardence in Oct 2023, through two sale and purchase agreements.
Accordingly, subsequent to the tranche 2 completion, the latest shareholding held by the group in Ardence Pharma is 82%.
For the FY2024 ended Dec 31, 2024, the group reported a revenue growth of 14.6% higher y-o-y at $195.4 million.
The group says its FY2024 revenue growth is due to the acquisition of Ardence Pharma which contributed $7.2 million in revenue.
See also: Ever Glory completes acquisition of Guthrie Engineering for $31.53 mil
Shares in Hyphens Pharma closed flat at 27.5 cents on May 9.
Scroll to continue
